Australia's largest stock trading and investment forum Australia's #1 stock forum

PER

34.1%

8.9¢ percheron therapeutics limited

anp chart, page-364

First 364 Last

Share
Profile

Follow
RYNZN

3,222 Posts.

574

19/04/23

19:43

Post #: 67363015
Share

Originally posted by itsagas: ↑

Did some DD on dystrophen

https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206488lbl.pdf See section 14 of the eteplirsen Product Information leaflet. After 48 weeks of treatment eteplirsen only increased dystrophin levels from 0.16% of health patients to 0.44%. The median (mid-range) increase after 48 weeks was only 0.1%

Golodirsen increased mean dystrophin levels from 0.10% (SD 0.07) of normal at baseline to 1.02%(SD 1.03) of normal by Week 48 of Study 1 Part 2, with a mean change in dystrophin of 0.92% (SD 1.01) of normal levels (p<0.001); the median change from baseline was 0.88
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211970s002lbl.pdf

DMD patients (like the MDX mice) have very low levels of dystrophin protein and these Sarepta drugs increased dystrophin in piatients to about 1% of healthy subjects after 48 weeks of treatment - so very low levels to detect!

Imo: Some investors didn’t understand Mondays announcement…

Sam: once again it was a very good post can you elaborate)

Anp does not require Dystrophen to be successful.. But after the extended study if it does show a tiny distrophen increase in the mice : it will be important to others.eg financiers.
and Pharmas and we might see a spike in the sp..
Don’t forget Sarepta only produced micro Dystrophen not the real dystrophenp

imo
We wait.

Expand

Sarepta increase dystophin by 1%....

so, if we can increase their drugs dystophin making capacity to eg 2% we have doubled their outcome.

We are continuing to test as the results werent sensitive enough.... possibly meaning not much was seen so now we are looking deeper.

...unlikely but funny if our results are so good xyz has asked for further confirmation.

ANP Price at posting: 8.0¢ Sentiment: Buy Disclosure: Held
4 Upvote

1 Great analysis

Reply

Top Stories

IRX

InhaleRX snags $38.5M in funding from VC biotech funder Clendon

TLG

Talga Group wins key permit for flagship graphite mine in Sweden

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

M4M

Macro, Norden set up transport solutions initiative for West Pilbara

MTH

Mithril's drilling in Mexico picks up silver at 997g/t, gold at 28g/t

Week 42 Wrap: HotCopper's top picks; new ASX 200 record; world yawns at war

SNX

Sierra Nevada raises $2M for silver exploration at Blackhawk

NVU

Nanoveu surges 10% after benchmark testing for new AI chip begins

SWP

Swoop lobs $18M offer at microcap telecom Vonex – in which it holds 19.9%

What's causing the cost-of-living crisis, and how to navigate it